Trial reportAge and ageing2026
Measuring what matters: evaluating the psychometric properties of goal attainment scaling in a psychosocial dementia trial.
Trial report in Age and ageing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt can be challenging to identify clinically meaningful, responsive primary outcomes for psychosocial intervention trials in people with dementia. Goal Attainment Scaling (GAS), a personalised, patient-generated outcome measure, enables individuals to define and evaluate progress toward meaningful goals. Evidence regarding its psychometric properties in dementia trials, however, remains limited.
objectiveTo evaluate the feasibility, reliability, and validity of GAS within the randomised controlled trial of NIDUS-Family (New Interventions in Dementia Study), a goal-based psychosocial intervention.
methods302 people with dementia and family carer dyads collaboratively set baseline goals toward supporting the person with dementia to live well at home. In a psychometric evaluation guided by the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) framework, we examined follow-up completion (measuring feasibility); rater agreement; intra-rater reliability; construct validity by assessing correlations between change in GAS and quality-of-life (DEMQOL-proxy and CarerQoL); and predictive validity by testing whether GAS change predicted living at home at 12 months.
resultsGAS completion rates were 86% at 6 months and 82% at 12 months. GAS demonstrated excellent inter-rater (Intraclass Correlation Coefficient = 0.99) and intra-rater reliability (Cohen's kappa = 0.91). There were significant but weak positive correlations between GAS change and carer and person with dementia quality-of-life (r = 0.14-0.22). GAS change was associated with remaining at home (odds ratio 1.08 per point increase; P <.01).
conclusionGAS is feasible, valid and reliable, so may be a sensitive and clinically meaningful candidate primary outcome for psychosocial dementia trials. Correlations with global quality of life were significant but modest, consistent with GAS capturing personalised rather than generic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.